PD-L1 Positron Emission Tomography Imaging in Patients With Non-Small Cell Lung Cancer : Preliminary Results of the ImmunoPET Phase 0 Study

The ImmunoPET Phase 0 study is a single-arm interventional study that has recruited 5 patients with stage IV non-small cell lung cancer (NSCLC). It aimed to establish the safety of 89Zr-durvalumab positron emission tomography (PET)/computed tomography (CT) to define the biodistribution of the tracer and determine optimum imaging time points for a subsequent phase 1 multicenter study of sequential 89Zr-durvalumab PET/CT scanning in patients treated with chemoradiation for stage 3 NSCLC.